BACKGROUND Cytochrome P450 family 8 subfamily B member 1 (CYP8B1) generates 12α-hydroxylated bile acids (BAs) that are associated with insulin resistance in humans.METHODS To determine whether reduced CYP8B1 activity improves insulin sensitivity, we sequenced CYP8B1 in individuals without diabetes and identified carriers of complete loss-of-function (CLOF) mutations utilizing functional assays.RESULTS Mutation carriers had lower plasma 12α-hydroxylated/non–12α-hydroxylated BA and cholic acid (CA)/chenodeoxycholic acid (CDCA) ratios compared with age-, sex-, and BMI-matched controls. During insulin clamps, hepatic glucose production was suppressed to a similar magnitude by insulin, but glucose infusion rates to maintain euglycemia were higher in mutation carriers, indicating increased peripheral insulin sensitivity. Consistently, a polymorphic CLOF CYP8B1 mutation associated with lower fasting insulin in the AMP-T2D-GENES study. Exposure of primary human muscle cells to mutation-carrier CA/CDCA ratios demonstrated increased FOXO1 activity, and upregulation of both insulin signaling and glucose uptake, which were mediated by increased CDCA. Inhibition of FOXO1 attenuated the CDCA-mediated increase in muscle insulin signaling and glucose uptake. We found that reduced CYP8B1 activity associates with increased insulin sensitivity in humans.CONCLUSION Our findings suggest that increased circulatory CDCA due to reduced CYP8B1 activity increases skeletal muscle insulin sensitivity, contributing to increased whole-body insulin sensitization.FUNDING Biomedical Research Council/National Medical Research Council of Singapore.
Shiqi Zhong, Raphael Chèvre, David Castaño Mayan, Maria Corlianò, Blake J. Cochran, Kai Ping Sem, Theo H. van Dijk, Jianhe Peng, Liang Juin Tan, Siddesh V. Hartimath, Boominathan Ramasamy, Peter Cheng, Albert K. Groen, Folkert Kuipers, Julian L. Goggi, Chester Drum, Rob M. van Dam, Ru San Tan, Kerry-Anne Rye, Michael R. Hayden, Ching-Yu Cheng, Shaji Chacko, Jason Flannick, Xueling Sim, Hong Chang Tan, Roshni R. Singaraja
Title and authors | Publication | Year |
---|---|---|
Bile acid metabolism in type 2 diabetes mellitus
Sandoval MC, Haeusler RA |
Nature reviews. Endocrinology | 2025 |
Unresolved alterations in bile acid composition and dyslipidemia in maternal and cord blood after UDCA treatment for intrahepatic cholestasis of pregnancy
Basu S, Običan SG, Bertaggia E, Staab H, Izquierdo MC, Gyamfi-Bannerman C, Haeusler RA |
American journal of physiology. Gastrointestinal and liver physiology | 2025 |
High-Fat Diet-Induced Decreased Circulating Bile Acids Contribute to Obesity Associated with Gut Microbiota in Mice.
Cai H, Zhang J, Liu C, Le TN, Lu Y, Feng F, Zhao M |
2024 | |
A new mechanism of thyroid hormone receptor β agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles.
Sun K, Zhu NL, Huang SL, Qu H, Gu YP, Qin L, Liu J, Leng Y |
Acta Pharmacologica Sinica | 2024 |
Bacteroides uniformis Ameliorates Carbohydrate and Lipid Metabolism Disorders in Diabetic Mice by Regulating Bile Acid Metabolism via the Gut–Liver Axis
Zhu XX, Zhao CY, Meng XY, Yu XY, Ma LC, Chen TX, Chang C, Chen XY, Zhang Y, Hou B, Cai WW, Du B, Han ZJ, Qiu LY, Sun HJ |
Pharmaceuticals | 2024 |
Implementation of the Methyl-Seq platform to identify tissue- and sex-specific DNA methylation differences in the rat epigenome.
Cox OH, Seifuddin F, Guo J, Pirooznia M, Boersma GJ, Wang J, Tamashiro KLK, Lee RS |
Epigenetics | 2024 |
Gut microbiota and metabolomic profile changes play critical roles in tacrolimus-induced diabetes in rats.
Jiang Z, Qian M, Zhen Z, Yang X, Xu C, Zuo L, Jiang J, Zhang W, Hu N |
Frontiers in cellular and infection microbiology | 2024 |
Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
Li T, Chiang JY |
Pharmacological Reviews | 2024 |
The bile acid chenodeoxycholic acid associates with reduced stroke in humans and mice
Monteiro-Cardoso VF, Yeo XY, Bae HG, Mayan DC, Wehbe M, Lee S, Krishna-K K, Baek SH, Palomera LF, Wu LH, Pakkiri LS, Shanmugam S, Sem KP, Yew MG, Parsons MP, Hayden MR, Yeo LL, Sharma VK, Drum C, Liehn EA, Sajikumar S, Davanger S, Jo DG, Chan MY, Tan BY, Jung S, Singaraja RR |
Journal of Lipid Research | 2024 |
Bear bile powder ameliorates type 2 diabetes via modulation of metabolic profiles, gut microbiota, and metabolites
Chen XL, Cai K, Zhang W, Su SL, Zhao LH, Qiu LP, Duan JA |
Frontiers in pharmacology | 2023 |
CYP8B1 downregulation mediates the metabolic effects of VSG
Yanjun Liu, Jui Tu, Linsen Shi, Zhipeng Fang, Mingjie Fan, Jianying Zhang, Lili Ding, Yiqiang Chen, Yangmeng Wang, Eryun Zhang, Senlin Xu, John Gillece, Lauren Reining, Sarah Highlander, Arthur Riggs, Lihua Jin, Wendong Huang |
Hepatology | 2023 |
Bile Acid Sequestration via Colesevelam Reduces Bile Acid Hydrophobicity and Improves Liver Pathology in Cyp2c70−/− Mice with a Human-like Bile Acid Composition
Palmiotti A, de Vries HD, Hovingh MV, Koehorst M, Mulder NL, Verkade E, Veentjer MK, van Dijk TH, Bloks VW, Havinga R, Verkade HJ, de Boer JF, Kuipers F |
Biomedicines | 2023 |
Decreased FXR Agonism in the Bile Acid Pool Is Associated with Impaired FXR Signaling in a Pig Model of Pediatric NAFLD.
Maj MA, Burrin DG, Manjarín R |
Biomedicines | 2023 |
In vivo mouse models to study bile acid synthesis and signaling
Bhattacharya A, Taylor RE, Guo GL |
Hepatobiliary & pancreatic diseases international : HBPD INT | 2023 |